Profil bibliographique

Kevin Bielamowicz

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

168Publications signalées

3557Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

CAR-T cell therapy researchCancer Immunotherapy and BiomarkersGlioma Diagnosis and TreatmentNeuroblastoma Research and TreatmentsImmunotherapy and Immune Responses

Publications récentes

2026 conference-abstractOpenAlex

Abstract CT270: Clinical trial in progress: BCC020 a dose escalation study using difluoromethylornithine (DFMO) and AMXT-1501 followed by a randomized controlled trial of DFMO with or without AMXT-1501 for neuroblastoma, CNS tumors, and sarcomas

Giselle Saulnier Sholler, Genevieve Bergendahl, Kevin Bielamowicz, Derek Hanson et autres

0 citationsCancer Research

2026 conference-abstractOpenAlex

Abstract 1173: Trans-species analysis of mismatch repair deficient IDH1 mutant gliomas reveals a unique genomic and immune landscape resulting in favorable response to combination immune and targeted therapy.

Vienna Mazzoli, Nicholas R. Fernandez, Zoya Aamir, Olha Kos et autres

0 citationsCancer Research

Accès ouvert 2025 articleOpenAlex

Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study

Alba Rubio‐San‐Simón, Lynley V. Marshall, François Doz, Jaume Catalá‐Mora et autres

3 citationsTargeted Oncology

Accès ouvert 2025 conference-abstractOpenAlex

CTNI-55. EXPLORING THE RELATIONSHIP BETWEEN PATIENT BASELINE CHARACTERISTICS WITH RESPONSES TO MIRDAMETINIB IN THE RENEU TRIAL OF CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMA (PN)

Timothy R. Gershon, Angela C. Hirbe, Hans Shuhaiber, David Viskochil et autres

0 citationsNeuro-Oncology

Accès ouvert 2025 articleOpenAlex

Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance

David K. Wilson, Sateesh Jayappa, Lora Parker, Eylem Öcal et autres

1 citationInternational Journal of Molecular Sciences

Accès ouvert 2025 articleOpenAlex

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors

Jessica Boklan, Anne‐Marie Langevin, Kevin Bielamowicz, Kathleen Neville et autres

1 citationCancers

Accès ouvert 2025 preprintOpenAlex

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors

Jessica Boklan, Anne‐Marie Langevin, Kevin Bielamowicz, Kathleen Neville et autres

1 citationPreprints.org

Accès ouvert 2025 preprintOpenAlex

TARGETED INHIBITION IN PEDIATRIC MET and ALK ALTERED PEDIATRIC HIGH GRADE GLIOMAS: OBJECTIVE RESPONSES FOLLOWED BY TREATMENT RESISTANCE

David K. Wilson, Sateesh Jayappa, Lora Parker, Eylem Öcal et autres

0 citations

Accès ouvert 2025 articleOpenAlex

Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma

Stephen Bagley, Yoshie Umemura, Joe Mendez, Isabel Arrillaga‐Romany et autres

3 citationsCancers

2025 articleOpenAlex

Navigating molecular neuropathology of CNS neoplasms for the practicing surgical pathologist

Brannon Broadfoot, Regina Kwon, Murat Gökden, Analiz Rodriguez et autres

0 citationsAmerican Journal of Clinical Pathology

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Figure 7 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function

Daniel Landi, Shoba A. Navai, Rebecca M. Brock, Kristen Fousek et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Figure 11 from A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function

Daniel Landi, Shoba A. Navai, Rebecca M. Brock, Kristen Fousek et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.